Real-world data. Real impact of Control-IQ on patients with T1D
The Control-IQ Observational (CLIO) study was designed to assess the safety and effectiveness of the Tandem t:slim X2 insulin pump with Control-IQ technology in the real-world outpatient setting. Due to its decentralized, virtual design, CLIO is the largest observational study of Control-IQ technology to date. A total of 3,157 patients were recruited for decentralized, virtual study participation between August 2020 and March 2022, with 95% of participants completing 12 month study duration.
Both adult and pediatric participants using Control-IQ technology experienced significantly lower severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) events than historically recorded through the T1D Exchange Registry. On average, adults using Control-IQ technology met the international Time in Range target of greater than 70% of the time between 70-180 mg/dL, device satisfaction was high, diabetes impact was reduced, and quality of sleep improved.?
Healthcare providers can continue to prescribe the t:slim X2 insulin pump with Control-IQ technology and a compatible continuous glucose monitoring system to patients with type 1 diabetes with confidence, knowing the benefits have been validated in real-world settings. See the full study here: https://doi.org/10.1089/dia.2023.0341 .
RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. Safety info: tandemdiabetes.com/safetyinfo ?
Rishi Graham, Lars Mueller, Michelle Manning, Steph Habif, Laurel H. Messer, Jordan E. Pinsker, and Eliah Aronoff-Spencer.
Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study.
Diabetes Technology & Therapeutics. ahead of print https://doi.org/10.1089/dia.2023.0341